There are currently 123 clinical trials in Mobile, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of South Alabama Mitchell Cancer Institute, MBCCOP - Gulf Coast, Mobile Infirmary Medical Center and University of South Alabama. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2024
Locations: University of South Alabama University Hospital, Mobile, Alabama
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
NCT05297734
Recruiting
This cluster-randomized comparative effectiveness trial compares a technology-based supportive cancer care (SCC) approach with a redesigned team-based supportive cancer care (SCC) approach.
Gender:
All
Ages:
21 years and above
Trial Updated:
03/20/2024
Locations: University of South Alabama, Mobile, Alabama
Conditions: End of Life, Cancer
Register for Updates
A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
NCT05862272
Recruiting
The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.
Gender:
Female
Ages:
Between 18 years and 50 years
Trial Updated:
03/14/2024
Locations: Mobile, Mobile, Alabama
Conditions: Uterine Fibroids, Endometriosis
Register for Updates
LOWER: Lomitapide Observational Worldwide Evaluation Registry
NCT02135705
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Gender:
All
Ages:
All
Trial Updated:
03/11/2024
Locations: Springhill Physician Practices, Mobile, Alabama
Conditions: Homozygous Familial Hypercholesterolemia
Register for Updates
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
NCT06283966
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Mobile, Alabama
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Register for Updates
A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
NCT05467176
Recruiting
This is a multi-center, prospective, observational study of patients being treated with ORGOVYX. The goal of this study is to generate real-world evidence about the safety and effectiveness of ORGOVYX in patients with prostate cancer in routine clinical care and the clinical course during treatment with and following cessation of ORGOVYX.
Gender:
Male
Ages:
18 years and above
Trial Updated:
03/08/2024
Locations: Urology Associates of Mobile, Mobile, Alabama
Conditions: Prostate Cancer
Register for Updates
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
NCT05210790
Recruiting
The study is designed to evaluate the safety and efficacy of rusfertide in subjects with polycythemia vera (PV) in maintaining hematocrit control and in improving symptoms of PV.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/03/2024
Locations: Infirmary Cancer Care, Mobile, Alabama
Conditions: Polycythemia Vera
Register for Updates
Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial
NCT03500328
Recruiting
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Ear... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/28/2024
Locations: The University of South Alabama, Mobile, Alabama
Conditions: Multiple Sclerosis, Relapsing-Remitting
Register for Updates
Project: Every Child for Younger Patients With Cancer
NCT02402244
Recruiting
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Gender:
All
Ages:
25 years and below
Trial Updated:
02/27/2024
Locations: USA Health Strada Patient Care Center, Mobile, Alabama
Conditions: Central Nervous System Neoplasm, Childhood Immature Teratoma, Childhood Langerhans Cell Histiocytosis, Childhood Mature Teratoma, Congenital Mesoblastic Nephroma, Lymphoproliferative Disorder, Myeloproliferative Neoplasm, Stromal Neoplasm, Carcinoma In Situ, Malignant Solid Neoplasm, Desmoid Fibromatosis, Ganglioneuroma, Melanocytic Neoplasm, Neuroendocrine Neoplasm
Register for Updates
Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation
NCT04088071
Recruiting
The primary purpose of this registry is to obtain real-world clinical experience of Paroxysmal (PAF) and Persistent (PsAF) Atrial Fibrillation ablation radiofrequency (RF) technologies. Data from the registry will be used to assess clinical outcomes, including procedural efficiency, safety, and long-term, effectiveness of catheter ablation with novel RF technologies in PAF and PsAF patients.
Gender:
All
Ages:
18 years and above
Trial Updated:
02/14/2024
Locations: Cardiology Associates of Mobile, Mobile, Alabama
Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
NCT05813288
Recruiting
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
Gender:
All
Ages:
Between 12 years and 99 years
Trial Updated:
02/09/2024
Locations: Research Site 30001-287, Mobile, Alabama
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Register for Updates
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: University of South Alabama Mitchell Cancer Institute, Mobile, Alabama
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates